3rd Circ. Ruling Isn't Last Word On Noncash Pay-For-Delay

Law360, New York (June 26, 2015, 8:37 PM EDT) -- The Third Circuit answered the initial question Friday of whether pay-for-delay deals have to include cash to face antitrust scrutiny when it revived a class action over a brand's promise not to launch an authorized generic, but attorneys say it's far from clear that pharmaceutical patent settlements using other alternatives to cash payouts would have the same fate.

In a unanimous decision, a three-judge panel overturned the dismissal of an antitrust suit challenging a Hatch-Waxman Act settlement GlaxoSmithKline PLC signed with Teva Pharmaceutical Industries Ltd. over...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.